... with platinum and etoposide combination therapy as first-line chemotherapy. However, it remains uncertain whether carboplatin and etoposide combination therapy (CE) and cisplatin and etoposide combination therapy (PE) have comparable treatment efficacy. In this retrospective analysis, we compared the efficacy...

... retrospectively reviewed the medical records of the patients diagnosed with recurrent or metastatic HNACC. We compared the survival outcomes, including survival time from recurrence/metastasis (OS) patients who received systemic chemotherapy with paclitaxel (200 mg/m 2 ) and carboplatin (area under the curve 6...

... with poor control of delayed chemotherapy-induced nausea and vomiting (CINV) in patients receiving carboplatin (CBDCA)-based chemotherapy. This study aimed to evaluate whether using palonosetron (PALO) as a 5HT 3 RA provides superior control with CINV than first-generation (1st) 5HT 3 RA in triplet...

...; Raymond W. Jang; Elena Elimova Background: Trimodality therapy (TMT) with neoadjuvant chemoradiotherapy (nCRT) using concurrent carboplatin plus paclitaxel (CP) followed by surgery is the standard of care for locoregional esophageal or gastroesophageal junction (GEJ) cancers. Alternatively, nCRT...

... invasion were treated with 2 courses of adjuvant carboplatin (area under the curve of 7, with 21-day interval). Those without this risk factor were managed by surveillance. Disease-free survival (DFS) and overall survival (OS) were estimated with the Kaplan-Meier method. Results: After a median follow-up...

... marked ototoxicity at the end of treatment. The mean hearing loss between initial and final audiometries showed a hearing loss at 4 and 8 kHz in both ears ( p = 0.002). Thirteen patients switched to carboplatin and 15 to a lower dose of cisplatin. The outcome was not significantly altered when cisplatin...

... with carboplatin (AUC 5 ) plus pemetrexed (500 mg/m 2 ), were collected prior to chemotherapy and 48 h after treatment. ELISA was used to quantify cCK18 and tCK18. Results: The male-to-female ratio was 3:1, and the median age of patients was 63 years. Patients who had a clinical benefit (complete response, partial...

...Richard Kim; Jennifer Byer; William J. Fulp; Amit Mahipal; William Dinwoodie; David Shibata Background: The development of distant metastases of squamous cell carcinoma of the anal canal (SCCA) is rare but has a poor prognosis. A combination of carboplatin and paclitaxel is commonly used...

... II trials combining ifosfamide, carboplatin and etoposide chemotherapy (ICE) showed favorable results. We therefore applied the ICE protocol to 13 patients (10 GBM, 3 anaplastic astrocytomas). Partial or complete remissions were not observed. None of the 13 patients survived progression-free for 6...

... patients received maintenance chemotherapy following a complete response to 6 cycles of primary induction chemotherapy, comprising 6 cycles of carboplatin (AUC = 5), paclitaxel (175 mg/m 2 ), and gemcitabine (800 mg/m 2 ) per protocol. Results: There were statistically significant PFS differences between...

...V. Surmont; J.G.J.V. Aerts; R.J. van Klaveren; K. Tournoy; K.Y. Tan; R.M. Vernhout; P.I.M. Schmitz; C. Legrand; H.C. Hoogsteden; J.P. van Meerbeeck Purpose: Carboplatin area under the curve (AUC) 5 ml/min on day 1 with gemcitabine 1,250 mg/m 2 on day 1 and day 8 is a widely used regimen in advanced...

... with advanced ovarian cancer. Methods: Women with stage III/IV epithelial ovarian carcinoma that presented with large-volume disease were treated with neoadjuvant intravenous paclitaxel and carboplatin for three 21-day cycles followed by cytoreductive surgery. If optimally debulked, patients received...

... of the study were to assess tolerability and feasibility of increasing doses of carboplatin (level 1: 300 mg/ m 2 on day 1, level 2: 350 mg/m 2 on day 1, level 3: 400 mg/m 2 on day 1) in combination with a fixed dose of vinorelbine (25 mg/m 2 on days 1 and 8) in advanced NSCLC. Forty-two patients entered...

...A. du Bois; W. Vach; M. Kiechle; U. Cramer-Giraud; H.G. Meerpohl Carboplatin has proven efficacy in the treatment of ovarian cancer and has been proven to be less toxic compared to the parent compound cisplatin. Nevertheless, emesis is still a major problem associated with carboplatin-containing...

...T. Schnabel; N. Zamboglou; C. Kolotas; A. Hartmann; G. Schmitt From 1987 to 1991, 100 evaluable patients with advanced head and neck carcinomas (T2–4, N0–3) were treated with radiotherapy and simultaneous carboplatin. Tumors were located in the oral cavity in 33 patients, oropharynx in 8 patients...

... neuropathy, ototoxicity, and occasional renal dysfunction. Carboplatin, a cisplatin analogue, is active against advanced ovarian cancer, with a presumed lower incidence of emesis, ototoxicity, neuropathy, and renal dysfunction. The Southwest Oncology Group initiated a phase HI randomized trial, in which 342...

... or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Carboplatin Chemotherapy Small...

...J. Depondt; P. Gehanno; M. Martin; G. Lelievre; B. Guerrier; C. Peytral; H. Schott; B. Pellae-Cosset In a prospective, randomized, multicenter study, neoadjuvant chemotherapy (CT) with carboplatin and 5-fluorouracil (5-FU) followed by locoregional treatment (LRT) was compared with locoregional...

... factor in this toxicity, and new platinum salts (chiefly carboplatin) have therefore been developed. Carboplatin has no renal toxicity at usual doses, and its use does not require concomitant hyperhydration. Its gastrointestinal, otologic, and general tolerability is excellent. In contrast, most patients...

...J.L. Pico; A. Ibrahim; L. Castagna; J.H. Bourhis; M. Chazard; D. Maraninchi; J.P. Droz Twenty-seven patients with poor-prognosis malignancies were treated with a combination (CARBOPEC) of fixed-dose etoposide (1,750 mg/m2), cyclophosphamide (6,400 mg/m 2 ), and escalating doses of carboplatin (from...